These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 18375237)

  • 1. Mechanism of action of niacin.
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinic acid: recent developments.
    Kamanna VS; Vo A; Kashyap ML
    Curr Opin Cardiol; 2008 Jul; 23(4):393-8. PubMed ID: 18520725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein A-I complexed with phospholipid promotes hepatic lipoprotein and apolipoprotein secretion in the perfused hamster liver.
    Song W; Chen J; Redinger RN
    J Investig Med; 1998 Dec; 46(9):460-9. PubMed ID: 9861782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
    Scanu AM; Bamba R
    Am J Cardiol; 2008 Apr; 101(8A):44B-47B. PubMed ID: 18375241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niacin and cholesterol: role in cardiovascular disease (review).
    Ganji SH; Kamanna VS; Kashyap ML
    J Nutr Biochem; 2003 Jun; 14(6):298-305. PubMed ID: 12873710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased binding of LDL and VLDL to apo B,E receptors of hepatic plasma membrane of rats treated with Fibernat.
    Venkatesan N; Devaraj SN; Devaraj H
    Eur J Nutr; 2003 Oct; 42(5):262-71. PubMed ID: 14569407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
    Olsson AG
    Expert Opin Pharmacother; 2010 Jul; 11(10):1715-26. PubMed ID: 20518616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs.
    Briand F; Magot T; Krempf M; Nguyen P; Ouguerram K
    Eur J Clin Invest; 2006 Apr; 36(4):224-30. PubMed ID: 16620283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein receptors.
    Lestavel S; Fruchart JC
    Cell Mol Biol (Noisy-le-grand); 1994 Jun; 40(4):461-81. PubMed ID: 8061563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Important considerations for treatment with dietary supplement versus prescription niacin products.
    Backes JM; Padley RJ; Moriarty PM
    Postgrad Med; 2011 Mar; 123(2):70-83. PubMed ID: 21474895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.
    Yeganeh B; Moshtaghi-Kashanian GR; Declercq V; Moghadasian MH
    J Nutr Biochem; 2005 Apr; 16(4):222-8. PubMed ID: 15808326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development.
    Chapman MJ
    Curr Med Res Opin; 2005; 21 Suppl 6():S17-22. PubMed ID: 16138937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
    Brown BG; Zhao XQ
    Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in niacin and lipid metabolism.
    Kamanna VS; Ganji SH; Kashyap ML
    Curr Opin Lipidol; 2013 Jun; 24(3):239-45. PubMed ID: 23619367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.